Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PAHC
BuyUnloved QualityPhibro Animal Health Corporation · Healthcare · United States · $1.5B · Avg Vol: $8M/d
COMPANY DESCRIPTION
Phibro Animal Health Corporation is a U.S.-based company developing, manufacturing, and marketing a diverse portfolio of animal health and nutrition products, including medicated feed additives, vaccines, and nutritional supplements. The company's competitive moat is built on its extensive industry experience, strong relationships with livestock producers, and a broad product offering vital for animal productivity and disease prevention. This integrated approach solidifies its position in the global animal health market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 942.3M | 977.9M | 1.0B | 1.3B | 11.2% | 1.5B | 1.3B | 1.4B | 2.4% |
| EPS | 1.21 | 0.81 | 0.06 | 1.19 | -0.6% | 2.43 | 1.29 | 1.42 | 6.1% |
| Shares | 40.5M | 40.5M | 40.5M | 40.5M | +0.1% | — | — | — | — |
| Debt | 470.5M | 510.0M | 525.5M | 761.6M | 17.4% | 795.6M | — | — | — |
| Equity | 262.4M | 282.5M | 256.6M | 285.7M | 2.9% | — | — | — | — |
| Op CF | 31.6M | 13.3M | 87.6M | 80.1M | 36.3% | 69.0M | — | — | — |
| Inv CF | -22.6M | -74.0M | -48.2M | -288.7M | — | — | — | — | — |
| Fin CF | 16.3M | 27.0M | -6.8M | 207.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PAHC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PAHC | Phibro Animal Health Corporation(you) | $1.5B | 74 | Buy |
| ETON | Eton Pharmaceuticals, Inc. | $1.7B | 72 | Buy |
| XERS | Xeris Biopharma Holdings, Inc. | $1.5B | 60 | Hold |
| COLL | Collegium Pharmaceutical, Inc. | $786M | 72 | Buy |
| PBH | Prestige Consumer Healthcare Inc. | $2.5B | 67 | Buy |
| PCRX | Pacira BioSciences, Inc. | $1.0B | 85 | Strong Buy |
| ANIP | ANI Pharmaceuticals, Inc. | $1.7B | 92 | Strong Buy |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.5B | 85 | Strong Buy |
| GTII.CN | Green Thumb Industries Inc. | $1.6B | 94 | Strong Buy |
| TRLV | Trulieve Cannabis Corp. | $2.3B | 90 | Strong Buy |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.3%